Burzynski Research Institute Inc

Burzynski Research Institute Inc

Stanislaw Burzynski, a Polish-American physician and biochemist, founded Burzynski Research Institute Inc in Houston, Texas, in the 1970s. The organization emerged from his research on antineoplastons—peptides and amino acid derivatives he claimed could treat cancer without the toxicity of conventional chemotherapy. The institute has operated as a for-profit clinical research entity, distinct from a typical family office structure. The institute's primary activity has been conducting clinical trials for antineoplaston therapy, targeting various cancers including brain tumors, prostate cancer, and breast cancer. Burzynski's work has been controversial, with the FDA investigating his practices and clinical trial designs. The organization does not publicly disclose an AUM or investment portfolio, and its capital appears largely tied to research operations. No named external portfolio companies, fund commitments, or co-investments are on record. The firm has a single known office in Houston, Texas. Team size is not publicly disclosed, and no philanthropic foundations or operating companies have been identified. The most recent operational event was the 2024 FDA approval of a new clinical trial protocol for antineoplastons in pediatric brain tumors (per FDA correspondence, 2024). The institute's structural differentiator is its singular focus on a proprietary drug class developed by its founder. Unlike typical family offices or biotech firms, the institute does not raise external capital or license its technology to partners—it operates as a closed, founder-controlled entity funding its own research pipeline.